Debra Times Seven for Sanofi-Aventis ADME Research
News Nov 08, 2007
The company is running the latest release of Debra (5.6.3) on a Citrix server in its Global Metabolism & Pharmacokinetic Department in Montpellier, with connections to Chilly-Mazarin, Alfortville, Frankfurt, Budapest and Bridgewater USA.
It has taken three years to implement the programme, beginning in 2004 with the decision to centralize and the choice of Debra as the LIMS best suited to meeting the needs of the different sites. User requirement specifications were drawn up in 2005 for development by LabLogic the following year. The system was validated in the first half of 2007 in time for implementation in June.
The harmonization resolves inconsistencies in LIMS practices following the Sanofi-Synthelabo / Aventis merger, as a result of which some sites had more experience of Debra than others and two were using different systems entirely.
"We anticipate that standardizing on Debra will reduce costs and help us to follow the same studies procedures at all our sites, but the biggest advantage is likely to be the sharing of data," said Valerie Gall of the Montpellier GMPK.
"With all our ADME compound information on a single database we will be able to compare studies from different sites quickly and easily."
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018